Abstract
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Reviews on Recent Clinical Trials
Title:What is the Current Role of Immunotherapy for Colon Cancer?
Volume: 11 Issue: 2
Author(s): Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Gonzalo Recondo, Máximo de la Vega and E. Diaz Cantón
Affiliation:
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Abstract: Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Export Options
About this article
Cite this article as:
Galanternik Fernando, Recondo Gonzalo, E. Valsecchi Matías, Greco Martín, Recondo Gonzalo, de la Vega Máximo and Diaz Cantón E., What is the Current Role of Immunotherapy for Colon Cancer?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330121851
DOI https://dx.doi.org/10.2174/1574887111666160330121851 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Integrins as A New Target for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Lectin Glycoarray Technologies for Nanoscale Biomedical Detection
Protein & Peptide Letters Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma
Current Cancer Drug Targets Azathioprine, Mucosal Healing in Ulcerative Colitis, and the Chemoprevention of Colitic Cancer: A Clinical-Practice-Based Forecast
Inflammation & Allergy - Drug Targets (Discontinued) Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Role of Imaging in Testicular Cancer
Current Medical Imaging Effect of Hsp90 Inhibitor KW-2478 on HepG2 Cells
Anti-Cancer Agents in Medicinal Chemistry Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer
Current Drug Delivery New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery